A number of promising clinical trials are underway investigating gene therapy for the treatment of neovascular AMD and this could be the way in which we treat this disease in the future. Basically a viral vector is used to delivery a gene encoding an anti-VEGF molecule thereby making the target cell a biofactory for anti-VEGF molecule production. There are a number of ways by which the gene can be delivered including subretinal, suprachoroidal and intravitreal strategies. In today’s video, guest surgeon of the week Dr. Michael Klufas will demonstrate the subretinal and suprachoroidal delivery of investigational RGX-314 or sura-vec, which is a gene therapy delivered via an AAV8 viral vector. If you haven’t already, be sure to watch our interview with Dr. Klufas in Podcast #22, where he talks about how to assess and get involved in clinical trials. Thank you Dr. Klufas for sharing this case!
Financial Dislclosures:
- Dr. Klufas in an investigator and consultant for Regenxbio/Abbvie
- Dr. Prasad has served as an advisory board member for Regenxbio/Abbvie
